A seismic shift is underway in the landscape of mental healthcare, spurred by an unexpected endorsement from a former president. Donald Trump recently signed an executive order designed to accelerate research, funding, and potential FDA approval of powerful psychedelic substances – ibogaine, psilocybin, LSD, and MDMA – offering a potential lifeline to those battling PTSD, depression, and addiction.
MIND-ALTERING BREAKTHROUGH: Is Psychedelic Healing Going MAINSTREAM?
